TTUHSC School of Medicine
HomeSchool of MedicineCell Biology & BiochemistryFaculty

Barry Maurer, M.D. Ph.D.

Associate Professor

Research Interests

His research focuses on retinoids, “vitamin A derivatives” as tumor-selective differentiation or cytotoxic agents, mechanisms of drug resistance and drugs to modulate resistance in childhood and adult cancers, development of novel preclinical testing models for childhood and adult cancer drug development, and clinical trials testing novel therapeutic approaches for cancer.

History & Education


1990 Wayne State University M D  
1990 California Institute of Technology Ph D  


1991-1993 LAC/USC Medical Center


199 -1997 Clinical Fellow Fred Hutchinson Cancer Research Center
1997-2000 Research Fellow Childrens Hospital Los Angeles Research Institute

Board Certification

2000 American Board of Pediatrics General Pediatrics  
2005 American Board of Pediatrics Hematology/Oncology  


1974 National Merit Scholarship
1980 NIH NRSA Predoctoral Traineeship
1987 Summer Science Research Program for Medical Students March of Dimes Birth Defects Foundation
1990 M.D. (Distinction in Biomedical Research)
2004 Eurand Award for Novel Approaches in Oral Drug Delivery, Controlled Release Society, 31st Annual Meeting 2004, for novel LXS oral fenretinide formulation.

Memberships & Affiliations

  • American Association of Cancer Research
  • International Society of Paediatric Oncology
  • Children's Oncology Group


  1. Holliday, Jr., M.W., Cox, S.B., Kang, M.H., and Maurer, B.J., “C22:0- and C24:0-dihydroceramides confer cytotoxicity in T-cell acute lymphoblastic leukemia cell lines.”  PLoS ONE, 8(9): e74768. doi:10.1371/journal.pone.0074768 (2013).
  2. Maurer, B.J., Kang, M.H., Janeba, J., Groshen, S., Matthay, K.K., Sondel, P.M., Maris, J.M., Jackson, H.A., Goodzarian, F., Shimada, H., Villablanca, J.G., Czarnecki, S., Hasenauer, B., Reynolds, C.P., and Marachelian, A., “Phase I Trial of Fenretinide Delivered Orally in a Novel Organized Lipid Complex in Patients with Relapsed Neuroblastoma: A Report from the NANT Consortium.”  Pediatr Blood Cancer, doi: 10.1002/pbc.24643. (2013)
  3. Shibina A, Seidel D, Somanchi SS, Lee DA, Stermann A, Maurer BJ, Lode HN, Reynolds CP, Huebener N. “Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.” J Mol Med (Berl). 91:459-72 (2013).
  4. Cooper, J.P., Hwang, K., Singh, H., Wang, D., Reynolds, C.P., Curley Jr., R.C., Williams, S.C., Maurer, B.J., Kang, M.H., “Fenretinide Metabolism in Humans and Mice: Utilizing Pharmacologic Modulation of its Metabolic Pathway to Increase Systemic Exposure.”  Br. J. Pharmacol.  163:1263-75 (2011).
  5. Kummar, S., Gutierrez, M.E., Maurer, B.J., Reynolds, C.P., Kang, M., Singh, H., Crandon, S., Murgo, A.J., Doroshow, J.H., “Phase I Trial of Fenretinide Lym-X-Sorb Oral Powder in Adults with Solid Tumors and Lymphomas.”  Anticancer Res.  31:961-966 (2011).
  6. Lee, JS., Singh, H., Maurer B.J., Reynolds C.P., Kang M.H., “A validated LC with fluorescence detection method for simultaneous determination of safingol and D-erythro-sphinganine in human plasma.” Chromatographia.  71;1087-1091  (2010).
  7. Horton, T.M., Sposto, R., Brown, P., Reynolds, C.P., Hunger, S.P., Winick, N.J., Raetz, E.A., Carroll, W.L., Arceci, R.J., Borowitz, M.J., Gaynon, P.S., Gore, L., Jeha, S., Maurer, B.J., Siegel, S.E., Biondi, A., Kearns, P.R., Narendran, A., Silverman, L.B., Smith, M.A., Zwaan, M.C., Whitlock, J.A.  “Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference.”  Pediatr Blood Cancer. 54:872-878 (2010).
  8. Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B., “Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 53:1111-3 (2009).
  9. Cheung E, Dorff T, Groshen S, Quinn DI, Reynolds, CP, Maurer B.J., Lara PN, Tsao-Wei DD, Twardowski P, Gandara DR, Chatta G, McNamara M, Pinski J:  Oral fenretinide in biochemically recurrent prostate cancer:  A California Cancer Consortium Phase II trial.  Clinical Genitourinary Cancer 7:43-50 (2009).
  10. Wang, H., Maurer, B.J., Liu, Y-Y., Wang, E., Allegood, J., Kelly, S., Symolon, H., Liu, Y., Merrill Jr., A., Gouaze-Andersson, V. , Yu, J., Giuliano, A., Cabot, M.C.: “N-(4-hydroxyphenyl)retinamide Increases Dihydroceramide and Synergizes with Dimethylsphingosine to Enhance Cancer Cell Killing.”  Mol Cancer Ther 7:2967-76. (2008).
  11. Zhou J., Sohn, J.,  Spee, C.,  Ryan, S.J.,  Maurer, B.J.,  Kannan, R.,  Hinton, D.R., "N-4-hydroxyphenyl retinamide augments laser-induced choroidal neovascularization in mice"  Invest Ophthalmol & Visual Sci,  49:1210-20   (2008).
  12. Kong, G., Wang, D., Wu, J., Konopleva, K., Andreeff, M., Ruvulo,P.P.,  and Maurer, B.J., “Synthetic Triterpinoid Cytotoxicity in Pediatric Acute Lymphoblastic Leukemia Cell Lines is Independent of Ceramide Increase but Synergized by N-(4-hydroxyphenyl)retinamide.”   Leukemia,  22:1258-62,  (2008).
  13. Maurer, B.J., Kalous, O., Yesair, D.W., Wu, X., Vratilova, J., Maldonado, V., Khankaldyyan, V., Frgala, T., Sun, B-C., McKee, R.T., Burgess, S.W.,  Shaw, W.A., and  C. P. Reynolds, “Improved Oral Delivery of N-(4-hydroxyphenyl)retinamide with Novel LYM-X-SORB™ Organized Lipid Complex in Mice.”  Clin Cancer Res. 13:3079-3086  (2007).
  14. Wu, X., Kim, Y., Sun, B-C., Moore, J.D., Shaw, W.A., and Maurer, B.J.  “Liquid chromatography method for quantifying D-threo-1-Phenyl-2-palmitoylamino-3- morpholino-1-propanol (D-threo-PPMP) in mouse plasma and liver” J Chromatogr B 837(1-2):44-8  (2006).
  15. Batra, S., Reynolds, C.P., and Maurer, B.J., “Fenretinide Cytotoxicity for Ewing’s Sarcoma (ES) and Primitive Neuroectodermal Tumor (PNET) Cell Lines is Decreased by Hypoxia and Synergistically Enhanced by Ceramide Modulators.”  Cancer Res  64:5415-5424  (2004).
  16. Reynolds, CP, Maurer B.J., and Kolesnik, RN:  "Ceramide synthesis and metabolism as a target for cancer therapy."  Cancer Lett.  206:169-180  (2004).
  17. Vratilova, J., Frgala, T., Maurer, B.J., and Reynolds, C.P. "Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)-retinamide in tissues."  Journal of Chromatography   808:125-30  (2004).
  18. Reynolds CP, Matthay KK, Villablanca JG, and Maurer B.J. “Retinoid therapy of high-risk neuroblastoma”.  Cancer Lett. 197:185-92  (2003).
  19. O’Donnell, P.H., Guo, W-X., Reynolds, C.P., and Maurer, B.J. “N-(4-hydroxyphenyl)- retinamide Increases Ceramide and Is Cytotoxic to Acute Lymphoblastic Leukemia Cell Lines, but Not to Non-Malignant Lymphocytes.”   Leukemia 16:902-10  (2002).
  20. Wang, H., Maurer, B.J., Reynolds, C.P. and Cabot, M.C.  “N-(4-Hydroxyphenyl)retinamide Elevates Ceramide in Neuroblastoma Cell Lines by Coordinate Activation of Serine Palmitoyltransferase and Ceramide Synthase.”  Cancer Res  61:5102-5105  (2001).
  21. Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, and Maurer B.J.:  “Retinoic-acid resistant neuroblastoma cell lines show altered myc regulation and high sensitivity to fenretinide.”  Med Ped Oncol  35:597-602  (2000).
  22. Maurer, B.J., Melton, L., Billups, C., Cabot, M.C., and Reynolds, C.P.  “Synergistic Cytotoxicity in Solid Tumor Cell Lines Between N-(4-hydroxyphenyl)retinamide and Modulators of Ceramide Metabolism.”  J Natl Cancer Inst  92:1897-1909 (2000).
  23. Maurer, B.J., Metelitsa, L.S., Seeger, R.C., Cabot, M.C., and Reynolds, C.P.:  “N-(4-hydroxyphenyl)retinamide Increases Ceramide and Reactive Oxygen Species and Induces Mixed Apoptoses/Necrosis in Neuroblastoma Cell Lines.”  J Nat Cancer Inst 91:1138-1146  (1999).
  24. Maurer, B.J., Ihnat, M.A., Morgan, C., Pullman, J., O’Brien, C., Johnson, S.W., Rasey, J.S., and Cornwell, M.M. “Growth of Human Tumor Cells in Macroporous Microcarriers Results in p53-independent, Decreased Cisplatin Sensitivity Relative to Monolayers.”  Mol Pharmacol  55:938-47  (1999).
  25. Rasey, J.S., Cornwell, M.M., Maurer, B.J., Boyles, D.S., Hofstand, P., Chin, L. and Cerveny, C.:  “Growth and Radiation Responses of Cells Grown in Macroporous Gelatin Microcarriers (CultiSpher-G).”  Br J Cancer 74 Suppl 27:78-81  (1996).
  26. Maurer, B.J., Lai, E., Hamkalo, B., Hood, L.E. and Attardi, G.:  “Novel Submicroscopic Elements Containing Amplified Genes in Human Cells.”  Nature, 327: 434-437  (1987).
  27. Maurer, B.J., Carlock, L., Wasmuth, J.J. and Attardi, G.:  “Assignment of Human Dihydrofolate Reductase Gene to Band q23 of Chromosome 5 and a Related Pseudogene -HD1 to Chromosome 3.”  Somat Cell Mol Genet  11: 79-86 (1985).
  28. Maurer, B.J., Barker, P.E., Masters, J.N., Ruddle, F.H., and Attardi, G.: “Human Dihydrofolate Reductase Gene is Located in Chromosome 5 and is Unlinked to the Related Pseudogenes.”  Proc Natl Acad Sci USA  81:1484-1488  (1984).
  29. McCombie, R.W., Hansen, J.B., Zylstra, G.J., Maurer, B.J., and Olsen, R.H.:  “Pseudomonas Streptomycin Resistance Transposon Associated With R-Plasmid Mobilization.”  J Bacteriol  165: 40-48  (1983).